A clinical trial of Ruxotemitide in combination with Lifileucel for the treatment of cancer
Latest Information Update: 25 Nov 2019
At a glance
- Drugs Lifileucel (Primary) ; Ruxotemitide (Primary)
- Indications Cancer
- Focus Therapeutic Use
Most Recent Events
- 25 Nov 2019 New trial record
- 10 Nov 2019 According to an Lytix Biopharma media release, the company announced a clinical collaboration with the US-based company Iovance Biotherapeutics to evaluate Lytix's first-in-class oncolytic peptide, LTX-315, in combination with Iovance's autologous ready to infuse T cell therapy.